David B. Resnik
Bioethicist, National Institute of Environmental Health Sciences
Posts by David B. Resnik
- From Bioethics Briefings
Nanotechnology
Read the PostFrom Bioethics BriefingsFraming the Issue Nanotechnology—the emerging field of manipulating matter at the nanoscale—is expected to become a key transformative technology of the twenty-first century. A nanometer (nm) is one billionth of a meter, which is the scale of individual atoms and molecules (a gold atom is 0.14 nm...Read the Post - From Bioethics Briefings
Environment, Ethics, and Human Health
Read the PostFrom Bioethics BriefingsFraming the Issue Many of the most challenging ethical questions of our time address interactions between human health and the environment. How should we regulate pesticides, industrial chemicals, and pollutants? Should we develop genetically modified organisms for use in agriculture, medicine, a...Read the Post - Bioethics Forum Essay
Charging Smokers Higher Health Insurance Rates: Is it Ethical?
Read the PostBioethics Forum EssaySmoking-related illnesses cost the United States hundreds of billions of dollars a year in health care expenditures and lost productivity, and claim hundreds of thousands of lives.” Given the enormous medical and economic toll of smoking, it is not surprising that 58 percent of Americans favor ch...Read the Post - Bioethics Forum Essay
A More Ethical Strategy Against Obesity: Changing the Built Environment
Read the PostBioethics Forum EssaySince the 1960s, obesity has become one of the most significant health problems in industrialized nations. In the U.S., the percentage of obese adults increased from 13 percent in the 1960s to 32 percent in 2004. According to some estimates, 41 percent of U.S. adults will be obese by 2015 and 75 p...Read the Post
Related Posts
PRESS RELEASE 1-04-2019: New in the Hastings Center Report
Read the Post- IRB: Ethics & Human Research
The Need to Track Payment Incentives to Participate in HIV Research
Read the PostIRB: Ethics & Human ResearchAbstract: Providing incentives is an accepted and common practice in human subjects research, including clinical HIV research. While we know that financial incentives among similar studies can greatly vary, surprisingly little research exists on how to determine when such incentives are excessive or ...Read the Post - IRB: Ethics & Human Research
Do U.S. Regulations Allow More than Minor Increase over Minimal Risk Pediatric Research? Should They?
Read the Post - IRB: Ethics & Human Research
Minor Changes to Previously Approved Research: A Study of IRB Policies
Read the PostIRB: Ethics & Human ResearchWe examined institutional review board (IRB) policies from the top U.S. research universities to determine how many have policies that define or provide examples of what constitutes a “minor change” to previously approved research. We sought to describe differences among definitions and to ascert...Read the Post - IRB: Ethics & Human Research
(Mis)Understanding Exploitation
Read the PostIRB: Ethics & Human ResearchThe notion of exploitation frequently crops up in discussions about the ethics of biomedical research. A standard concern about clinical trials is that they exploit research subjects for the benefit of future patients. This concern is particularly emphasized when participants in clinical trials are d...Read the Post - IRB: Ethics & Human Research
Genomic Research Data: Open vs. Restricted Data
Read the PostIRB: Ethics & Human ResearchOpenness is one of science’s fundamental ethical norms, but it should not take precedence over the obligation to protect the confidentiality of data. Deidentifying the data obtained from human genomic research as a condition of providing open access to research data is a strategy to promote scienti...Read the Post - IRB: Ethics & Human Research
Oncology Consent Forms: Failure to Disclose Off-Site Treatment Availability
Read the PostIRB: Ethics & Human ResearchMany research studies investigate new uses of medications that are commercially available.1 For example, cancer researchers often conduct studies to determine whether a chemotherapy agent approved by the Food and Drug Administration (FDA) to treat one type of cancer is also effective at treating a di...Read the Post PRESS RELEASE: 4-30-2013 The Ethics of Knowledge: When Should Hazardous Scientific Information be Made Public?
Read the Post(Garrison, NY) How can we best address the potential threat posed by “dual use” research – scientific findings that can be used for good or evil? An article and two commentaries in the Hastings Center Report examine this question in relation to the controversial decision to allow full pub...Read the Post